News List

Strand Life Sciences secures investment from Quadria Capital


Strand Life Sciences has secured an investment by Quadria Capital. HealthQuad Fund and Heritas Venture Fund have also contributed to this investment.

By Team ABLE

Bengaluru-based Strand Life Sciences has announced an investment by healthcare focused private equity investor Quadria Capital. India-based HealthQuad Fund and Singapore-based Heritas Venture Fund have also contributed to this fund.
According to the company’s press release this investment will be utilized to fund the growth and expansion of Strand towards becoming Asia’s leading integrated diagnostics company. Chief Executive Officer Strand Life Sciences, Dr. Ramesh Hariharan, said, “Given their deep operating knowledge and experience of building healthcare businesses in Asia, the partnership with Quadria and HCG will help launch Strand into its next phase of growth and into an era where data analytics and molecular measurements together change diagnosis and treatment paradigms.”

Strand now offers end-to-end capabilities in precision medicine – a complete range of clinical diagnostic offerings including oncology, women’s health, fertility, genetics, infectious diseases and preventive care, on-ground presence through 15 laboratories in a mix of metros and emerging cities, globally renowned bioinformatics capabilities used by global instrument providers and diagnostic laboratories, and access to India’s largest cancer biorepository for cutting-edge clinical research.

Quadria Capital Managing Partner and Co-Founder Dr. Amit Varma, said, “The demand for specialized diagnostics has been rising rapidly across the region. With diagnostics moving beyond just identification of infections to becoming an integral part of management and therapy, we see a huge potential in this area. Quadria is very excited to partner with Strand in this unique diagnostic platform that provides a potent combination of world class bioinformatics, genomics research, and integrated specialized diagnostics.”

Congratulating Strand Life Sciences on the agreement, industry veteran Kiran Mazumdar-Shaw, Biocon, Chairman, said, “Strand’s partnership with Triesta is an inflection point which I am confident will drive its future into the fast growing segment of genomic led onco-diagnostics. This merger has attracted a significant investment from Quadria Capital which endorses the credibility of Strand’s evolving business strategy.”